Reference health
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
35/35 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 35 checked references that resolve
resolves10.1182/blood-2003-06-2031
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
resolves10.1200/JCO.2008.19.9117
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
resolves10.1002/art.23732
Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study
resolves10.1182/blood-2007-10-117671
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
resolves10.1182/blood-2008-04-149161
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
resolves10.1182/blood.V83.2.435.435
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
resolves10.1182/blood-2004-01-0039
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
resolves10.4049/jimmunol.177.1.362
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
resolves10.1182/blood-2006-04-020057
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
resolves10.1158/0008-5472.CAN-08-2033
Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics
resolves10.1002/bit.20777
Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II
resolves10.1182/blood-2002-06-1761
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
resolves10.1007/s00262-001-0247-1
Binding to CD20 by Anti-B1 Antibody or F(ab') 2 is sufficient for induction of apoptosis in B-cell lines
resolves10.1182/blood.V112.11.234.234
A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease
resolves10.1182/blood-2007-02-074716
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
resolves10.1182/blood.V99.3.754
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
resolves10.1200/JCO.2003.05.013
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
resolves10.1200/JCO.2007.14.8957
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/
<i>neu</i>
–Positive Metastatic Breast Cancer
resolves10.1200/JCO.2008.18.0463
Impact of FcγRIIa-FcγRIIIa Polymorphisms and <i>KRAS</i> Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
resolves10.1038/nm736
Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
resolves10.3324/haematol.13690
Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton
resolves10.1182/blood-2006-12-062927
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
The 5 references without a DOI — listed, not checked
no DOI — not checkedCD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100–insoluble membrane rafts.
no DOI — not checkedAntigen binding molecules with increased Fc receptor binding affinity and effector function.
no DOI — not checkedGlycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity.
no DOI — not checked2019111800034649600_B22
no DOI — not checkedAntigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection [published online ahead of print March 16, 2010].
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1182/blood-2009-06-225979"><img src="https://citestamp.com/citestamped/10.1182/blood-2009-06-225979/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1182/blood-2009-06-225979)